How many insider trades does FilingIQ track for BYSI?

FilingIQ tracks 70 Form 4 insider transactions for BYSI (BeyondSpring Inc.), covering filings from Jun 17, 2025 onwards. 7 of those were filed in the last 90 days.

Are BYSI insiders net buyers or net sellers?

Across the full Form 4 history for BYSI, 0 transactions (0%) were open-market purchases and 63 (90%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does BYSI insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is BYSI in?

BeyondSpring Inc. (BYSI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $69.09M.

BYSI insider trading

NasdaqCM Healthcare

BeyondSpring Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 90%

Market cap

$69.09M

About BeyondSpring Inc.

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Company website: beyondspringpharma.com

BYSI insider activity at a glance

FilingIQ has scored 70 insider transactions for BYSI since Jun 17, 2025. The most recent filing in our index is dated Apr 1, 2026.

Across the full history, 0 open-market purchases and 63 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on BYSI insider trades is 43.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live BYSI trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding BYSI

Decheng Capital Management III (Cayman), LLC

$3.97M · 1.3% of AUM

Frequently asked

How many insider trades does FilingIQ track for BYSI?: FilingIQ tracks 70 Form 4 insider transactions for BYSI (BeyondSpring Inc.), covering filings from Jun 17, 2025 onwards. 7 of those were filed in the last 90 days.
Are BYSI insiders net buyers or net sellers?: Across the full Form 4 history for BYSI, 0 transactions (0%) were open-market purchases and 63 (90%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BYSI insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is BYSI in?: BeyondSpring Inc. (BYSI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $69.09M.

Methodology & sources

Every BYSI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.